OnKure Therapeutics, Inc. (OKUR)
NGM · Healthcare · Biotechnology
$4.20
-1.18%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$169.7M
Shares Outstanding
40.4M
Exchange
NGM
Currency
USD
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -16.3M | -15.5M | -14.1M | -15.6M |
| Net Income | -15.4M | -14.7M | -13.5M | -15.2M |
| Diluted EPS | $-1.14 | $-1.09 | $-0.99 | $-1.11 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -29.8M | -36.9M | -54.4M | -63.0M |
| Net Income | -29.5M | -35.3M | -52.7M | -59.5M |
| Diluted EPS | $-2.21 | $-2.65 | $-15.28 | $nan |